Close Menu

NEW YORK – Veracyte has taken an exclusive global license to NanoString Technologies' nCounter platform for diagnostic use and has obtained the rights to NanoString's 510(k)-cleared Prosigna breast cancer prognostic test and research-use LymphMark lymphoma subtyping assay, the companies said after the close of the market Tuesday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.